

August 10, 2018

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

**Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated)
for the Quarter ended June 30, 2018**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2018.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary & Legal Head



Encl: As above

Dr. Lal PathLabs Limited records revenue growth of 17.3% to Rs.2923 mn in Q1FY2018-19.

New Delhi, India, Aug 10, 2018 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2018

Consolidated Performance Highlights: Q1FY2018-19 vs. Q1FY2017-18
Revenue growth: 17.3% at Rs 2923 mn,
Normalised EBITDA at Rs 793 mn, PBT at Rs 754 mn
Normalised EBITDA margins at 27.1% vs 27.3% last year and
PAT Rs.497 mn with margin at 17%

- Operating Revenue increased by 17.3% in Q1 to Rs. 2993 million vs Rs 2493 million in the previous year same quarter. Underlying volume growth is 18.1% during the quarter.
- Normalised EBITDA in Q1FY19 grew 16.7% to Rs.793 million from Rs 680 million in the same quarter last year, after adjustment for RSU, other stock based compensation costs and CSR expense.
- EBITDA Margin has remained consistent at 27.1% for Q1 FY19 vs 27.3% in Q1 FY18.
- PBT was Rs 754 mn in Q1 vs Rs 660 mn in Q1 last year.
- Profit after Tax in Q1FY19 at Rs. 497 million compares with Rs 444 million in Q1 last year.

Financial Overview (Consolidated) in Rs mn

Particulars (Rs Mn.)	JQ 18	JQ 17	Gr %	FY'18
Total Revenue	2,922.8	2,492.6	17.3%	10,569.2
Total Expenditure	2,172.5	1,837.5		7,929.2
EBITDA	750.3	655.1	14.5%	2,640.0
Adj for RSU, stock based comp. & CSR cost	43.0	24.8		142.7
Normalised operating EBITDA	793.3	679.9	16.7%	2,782.7
<i>Normalised Margins</i>	<i>27.1%</i>	<i>27.3%</i>		<i>26.3%</i>
Other income incl. interest	93.7	74.6		312.2
PBT	753.5	660.3	14.1%	2,613.2
<i>Margins</i>	<i>25.8%</i>	<i>26.5%</i>		<i>24.7%</i>
PAT	496.5	444.3	11.7%	1,717.9
<i>Margins</i>	<i>17.0%</i>	<i>17.8%</i>		<i>16.3%</i>
EPS (Basic)	6.00	5.40	11.1%	20.85
EPS (Diluted)	6.00	5.40	11.1%	20.82

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range



of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR

+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.